Boston Scientific (NYSE:BSX) Given New $78.00 Price Target at Barclays

Boston Scientific (NYSE:BSX – Free Report) had its price objective lifted by Barclays from $70.00 to $78.00 in a report published on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the medical equipment provider’s stock. A number of other research firms have also weighed in on BSX. Citigroup increased their price objective […]

Related Keywords

Boston ,Massachusetts ,United States ,Canada ,Raymond James ,John Bradley Sorenson ,Wendy Carruthers ,Robertw Baird ,Citigroup ,Barclays ,Royal Bank ,Boston Scientific ,Investment Counselors ,Boston Scientific Corporation ,Frazier Financial Advisors ,Jones Financial Companies Lllp ,Bruceg Allen Investments ,Free Report ,Moderate Buy ,Get Free Report ,Bradley Sorenson ,Financial Advisors ,Financial Companies Lllp ,Scientific Corporation ,Boston Scientific Daily ,Nyse Bsx ,Bsx ,Medical ,10113710 ,Boost Price Target ,Barclays Plc ,